Why the Immuron (ASX:IMC) share price rocketed another 17% today

The biotech company is experiencing another healthy share jump today.

| More on:

Should you invest $1,000 in Insignia Financial right now?

Before you buy Insignia Financial shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Insignia Financial wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Immuron Ltd (ASX: IMC) share price soared again today, trading up 16.67% at 14 cents near the market close.

This follows a massive trading day as the company cemented its place as one of the best performers on the ASX yesterday with its share price seeing a whopping 31% increase.

So what happened with this Melbourne-based biotech company to make it reach such impressive prices?

Let's take a look…

Diarrhoea drug to hit Europe

At its core, Immuron focuses on creating and commercialising oral immunotherapies that both prevent and treat gut-related ailments.

It has two main products — Travelan, an over-the-counter oral medicine used to treat traveller's diarrhoea — and Protectyn, an immune supplement (sold by practitioners) supporting both digestive and liver function.

Today, the biotech company announced it had received a European patent for its treatment of traveller's diarrhoea.

Immuron advised that European Patent 3159357 — the "composition and method for the treatment and prevention of enteric bacterial infections — would give it the exclusive rights in several European countries.

The company already holds an existing patent position in Australia, India, Canada and the United States.

Once the patent is validated, Immuron will be able to sell its drug composition in France, Spain, Sweden, Austria, Germany, Denmark, Finland, Greece and the United Kingdom.

US military focus on Travelan

According to Immuron, traveller's diarrhoea not only is the most common form of illness for visitors to developing countries but also afflicts US troops that are deployed overseas.

In fact, prevention of the illness is a high priority for the US Military.

"The morbidity and associated discomfort stemming from diarrhea decreases daily performance, affects judgement, decreases morale and declines operational readiness," Immuron said in today's announcement.

And its not just only the short term effects Immuron considers worrisome — the medical community is now recognising that the illness can have serious post-infectious after-effects, inducing irritable bowel syndrome and other autoimmune diseases.

As such, the biotech company was awarded a $6.2 million Travelan clinical trial agreement by the United States Department of Defence yesterday — the first of several trials expected to undertaken with the military this year.

After releasing the news, the Immuron share price jumped just over 30% before lunchtime trade.

Immuron share price snapshot

Despite its recent positive moves, the Immuron share price has dropped 36% over the past 12 months. In fact, it saw its 52-week-low on Tuesday, when it hit 9 cents.

Since then, shares in the company have rebounded an impressive 55%.

The biotech company has a market capitalisation of $31 million and more than 277 million shares issued.

Motley Fool contributor Alice de Bruin has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »